| Ytd | 6.50% | |
| 1y | -34.30% |
| Open | 2.90 | Prev Close | 2.92 | Low | 2.89 | High | 2.99 | Mkt Cap | 12.71M |
| Vol | 9.07K | Avg Vol | 53.71K | EPS | -1.85 | P/E | -1.58 | Forward P/E | -1.06 |
| Beta | 1.55 | Short Ratio | 2.39 | Inst. Own | 3.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.14 | 200-d Avg | 3.05 | 1yr Est | 4.57 |
BLRX News
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses,
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses,
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- B
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with st
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neur
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel s
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage respons
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the mar
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents p
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ --
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Iri
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small mol
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ --
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-ex
BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin -
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly
On Friday morning, 446 companies hit new 52-week lows.
Monday saw 825 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
Before 10 a.m. ET on Tuesday, 166 companies hit new 52-week highs.
Stocks Which Set New 52-Week Low Friday, October 26th